Ryan Deschner
Stock Analyst at Raymond James
(4.66)
# 114
Out of 4,829 analysts
11
Total ratings
90%
Success rate
24.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Downgrades: Outperform | $75 → $52 | $17.30 | +200.58% | 1 | May 9, 2025 | |
| LQDA Liquidia | Maintains: Strong Buy | $27 → $29 | $15.26 | +90.04% | 3 | May 9, 2025 | |
| INZY Inozyme Pharma | Maintains: Outperform | $24 → $12 | $1.15 | +943.48% | 1 | Mar 12, 2025 | |
| TRVI Trevi Therapeutics | Upgrades: Strong Buy | $9 → $29 | $6.60 | +339.39% | 2 | Mar 10, 2025 | |
| ARDX Ardelyx | Reiterates: Strong Buy | $15 → $13 | $3.62 | +259.12% | 1 | Feb 21, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $13.44 | +108.33% | 3 | Jan 14, 2025 |
Apellis Pharmaceuticals
May 9, 2025
Downgrades: Outperform
Price Target: $75 → $52
Current: $17.30
Upside: +200.58%
Liquidia
May 9, 2025
Maintains: Strong Buy
Price Target: $27 → $29
Current: $15.26
Upside: +90.04%
Inozyme Pharma
Mar 12, 2025
Maintains: Outperform
Price Target: $24 → $12
Current: $1.15
Upside: +943.48%
Trevi Therapeutics
Mar 10, 2025
Upgrades: Strong Buy
Price Target: $9 → $29
Current: $6.60
Upside: +339.39%
Ardelyx
Feb 21, 2025
Reiterates: Strong Buy
Price Target: $15 → $13
Current: $3.62
Upside: +259.12%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $13.44
Upside: +108.33%